Trinity Biotech plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRIB research report →
Price Chart
About the company
Trinity Biotech plc, an Irish enterprise founded in 1992 and headquartered in Bray, is engaged in the acquisition, development, manufacturing, and global distribution of medical diagnostic solutions. The company's reach extends to the Americas, Africa, Asia, and Europe, catering to both clinical laboratory and point-of-care diagnostic markets. Its extensive range of clinical laboratory offerings encompasses diagnostic tests and specialized instrumentation for identifying numerous infectious diseases.
- CEO
- John Gillard
- IPO
- 1992
- Employees
- 287
- HQ
- Bray, WW, IE
Get TickerSpark's AI analysis on TRIB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $126.37M
- P/E
- -0.12
- PEG
- -0.00
- P/S
- 3.06
- P/B
- -0.05
- EV/EBITDA
- -54.55
- Div Yield
- 0.00%
- Gross Margin
- 38.48%
- Op Margin
- -17.97%
- Net Margin
- -78.88%
- ROE
- 48.72%
- ROIC
- -8.72%
Latest fiscal year · YoY change
- Revenue
- $43.78M-28.9%
- Gross Profit
- $16.89M-21.2%
- Op Income
- $-11,416,000
- Net Income
- $-37,376,000-17.6%
- EPS
- $-60.00-13.3%
- OCF Growth
- -41.5%
- FCF Growth
- +14.8%
- 52W High
- $52.50
- 52W Low
- $4.54
- 50D MA
- $6.70
- 200D MA
- $14.14
- Beta
- 0.99
- RSI (14)
- 40
- Avg Volume
- 13.45K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Trinity Biotech said Q3 revenue grew slightly, losses improved meaningfully, and the company remains focused on a late-2024/early-2025 transformation that it says should lift profitability and support future growth products.· November 15, 2024
- Q3 revenue was $15.2 million, up just over 3% year over year, led by a 60% increase in point-of-care revenue to $4.3 million.
- Gross profit was $5.3 million with a 35% gross margin; operating loss improved to $2.6 million from $4.5 million in Q3 2023.
- Management reiterated 2024 TrinScreen HIV sales of approximately $10 million and said it expects about $3 million from TrinScreen in Q4.
- The company reiterated its target of about $20 million annualized EBITDASO and about $75 million annualized run-rate revenue by Q2 2025.
- Leadership said NASDAQ listing deficiencies were resolved, and it expects major cost actions to finish by end-2024 or early 2025, with more impact in 2025.
Q3 2024 revenue was $15.2 million, up just over 3% from Q3 2023. Point-of-care revenue increased by $2.7 million to $4.3 million, up 60%, while clinical laboratory revenue was $10.8 million, down 9% year over year. Gross profit was $5.3 million and gross margin was 35%. Operating loss was $2.6 million versus $4.5 million in Q3 2023; adjusted EBITDASO loss was $1.4 million versus $3.5 million; and basic loss per ADS was $0.46 versus $0.88. Cash fell from $5.3 million at June 30 to $2.8 million at September 30, and cash used in operations was $3.6 million. Guidance: the company reiterated 2024 TrinScreen sales of approximately $10 million, expects about $3 million in Q4 TrinScreen revenue, and reiterated approximately $20 million annualized EBITDASO and approximately $75 million annualized run-rate revenue by Q2 2025.
John Gillard framed the quarter as part of a broader company transformation, emphasizing long-term growth from CGM, new diagnostics, and an improved operating model. He highlighted a second pre-pivotal CGM trial starting this week, inbound interest from commercial and strategic partners, and manufacturing/supply chain relationships aimed at scaling globally. His tone was confident and upbeat, repeatedly stressing that Trinity is “on the cusp” of a near-term step change in profitability while also preparing for future growth.
Louise Tallon focused on the quarter’s financial improvement and cost discipline. She said gross profit was $5.3 million at a 35% margin, SG&A declined to $6.5 million from $7.7 million, restructuring costs were about $300,000 in the quarter and $2.3 million year to date, and operating loss improved to $2.6 million. She also noted $2.1 million was capitalized for biosensor development, net financial expense rose by about $200,000 due to term loans tied to the Waveform transaction, and cash ended the quarter at $2.8 million after $3.6 million of operating cash outflow and $3.1 million of investment outflows.
Analysts pressed for clarity on TrinScreen, the hemoglobin business, the timing of cost savings, and the commercialization path for the acquired prostate cancer and preeclampsia tests. Management said TrinScreen should contribute about $3 million in Q4, that the lower hemoglobin/instrument revenue was mostly timing-related and partly a deliberate pause while the new column proposition rolls out, and that the core consumables business is broadly consistent. On the tuck-in deals, Trinity said the preeclampsia test should be revenue-generating in the second half of 2025 and the prostate cancer test in 2026, both initially offered as lab-developed tests through its New York State certified lab. Management also said current ATM capacity is less than $1 million.
The bull case from this call is that revenue is growing again while costs are being actively reduced, with Q3 showing higher revenue, better gross profit, and much smaller operating losses. Management is pointing to multiple near-term catalysts: offshore manufacturing, factory consolidation, corporate service offshoring, and new products in CGM and diagnostics that could add future growth. The company also regained NASDAQ compliance, which management said removes an overhang on the stock.
The main risks are that the profitability improvements are still mostly ahead rather than already visible in the numbers, and cash declined to $2.8 million at quarter-end. Revenue remains exposed to uneven ordering patterns, especially in rapid HIV, while hemoglobin revenue fell sharply year over year and instrument sales are being intentionally de-emphasized. The new growth programs are still in development, and management’s commercialization timelines for the acquired tests stretch into 2025 and 2026.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 78.7%
- Shares Outstanding
- 1.01M
- Float Shares
- 796.45K
of shares held by institutions
20 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Susquehanna International Group, Llp | 26.86K | ▲ 26.86K |
| Hunter Associates Investment Management LLC | 24.64K | ▼ 636.57K |
| Raymond James Financial Inc | 20.32K | 0 |
| Wells Fargo & Company/Mn | 2.50K | 0 |
| Colonial Trust Advisors | 350 | ▲ 350 |
| Jones Financial Companies Lllp | 331 | ▼ 3.31K |
| Rhumbline Advisers | 311 | ▼ 9.06K |
| Cibc Private Wealth Group LLC | 222 | 0 |
| Ubs Group AG | 171 | ▼ 936 |
| Osaic Holdings, Inc. | 149 | ▼ 3.35K |
| Morgan Stanley | 66 | ▼ 334 |
| Mcilrath & Eck, LLC | 5 | ▲ 5 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | O'Caoimh Ronan | other | 0 |
| Jun 14, 21 | O'Caoimh Ronan | other | 0 |
| Nov 17, 22 | O'Caoimh Ronan | other | 0 |
| Mar 20, 23 | O'Caoimh Ronan | other | 0 |
| Jan 1, 26 | O'Caoimh Ronan | other | 0 |
| Jan 1, 27 | O'Caoimh Ronan | other | 0 |
| Mar 18, 26 | Murphy Paul | other | 0 |
| Mar 18, 26 | Tivnan John Paul | other | 0 |
| Oct 1, 25 | Gillard John | other | 0 |
| Jan 1, 24 | Gillard John | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TRIB coverage
Recent articles, reports, and earnings notes.
No research on TRIB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TRIB report →Head-To-Head Survey: Trinity Biotech (NASDAQ:TRIB) vs. OrthoPediatrics (NASDAQ:KIDS)
defenseworld.net · Oct 19
Trinity Biotech's Trinovium Subsidiary Signs Contract to Supply Red Team Investments with Advanced Liquid Cooling Solutions for AI Data Center Infrastructure
globenewswire.com · Sep 9
Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update
globenewswire.com · Aug 28
Trinity Biotech's Trinovium Subsidiary Agrees to Collaborate with Echelon Data Centres to Develop Advanced Liquid Cooling Solutions for AI Infrastructure
globenewswire.com · Aug 17
Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement
globenewswire.com · Aug 14
Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology
globenewswire.com · Jul 22
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
globenewswire.com · Jul 22
New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring
globenewswire.com · Jul 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.